Navigation Links
Valeant Announces Pricing of Senior Notes
Date:11/18/2010

MISSISSAUGA, Ontario, Nov. 18, 2010 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, has priced its previously announced offering of senior unsecured notes which consists of $1 billion of 6.875% Senior Notes due 2018 (the "Notes"). The $1 billion aggregate principal amount of the Notes was increased from the previously announced offering size of $700 million. The offering is expected to close on or about November 23, 2010.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to qualified institutional buyers under Rule 144A of the Securities Act and outside the United States under Regulation S of the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.  

The notes will be guaranteed by the Company and each of the Company's subsidiaries (other than Valeant) that is a guarantor under Valeant's senior secured credit facilities.

Valeant intends to use the net proceeds from the offering of the Notes to repay its tranche B term loan facility under its credit facilities and for general corporate purposes, including acquisitions, debt repayment and share repurchases (including pursuant to its recently announced securities repurchase pro
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... test for diagnosing type-1 diabetes could improve patient ... disease, according to the device,s inventors at the ... a paper to be published online July 13 ... nanotechnology to detect type-1 diabetes outside hospital settings. ... forms of diabetes mellitus, which are both characterized ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... a Japanese study have given drug giant Novartis AG, ... The Lancet, the company’s blood pressure// drug Diovan was observed ... up to 40 percent. , The study titled the ... to 79, with high blood pressure, ischemic heart disease or ...
... from MetroHealth Medical Center and Case Western Reserve University ... have had previous spontaneous preterm births with 17 Alpha ... preterm birth would consequently reduce both short-term and lifetime ... The results of their study are reported in the ...
... study has showed that a particular group of its citizens; ... lion’s share of the arthritis// population, as well as its ... study, Edward Yelin, professor of medicine and health at the ... those with arthritis and other rheumatic conditions have increased to ...
... medication errors, says a new study by University of Arizona ... the journal Medical Care. ,The study was conducted ... professor Daniel C. Malone, Ph.D., who is also a member ... at the Critical Path Institute. ,Researchers reviewed data ...
... associated with depression in women, according to researchers at ... study being published in a recent issue of Preventive ... and depression in women. In addition, self-weighing daily, rather ... lower Body Mass Index (BMI) levels in women 40 ...
... Jose Gomes Temporao on Wednesday signed a decree declaring that ... generic version of Merck's// antiretroviral Efavirenz if the company does ... ,According to the decree, Efavirenz is a "public interest" ... not issue the decree "as a threat, nor to lower ...
Cached Medicine News:Health News:Novartis Drug Diovan Shows Superior Benefits 2Health News:Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs 2Health News:America’s Arthritis Patients Take Sizeable Chunks Of Healthcare Econom 2Health News:Pharmacists' Workload Contributes To Errors 2Health News:Brazil Will Purchase Merck’s Antiretroviral If Price Not Lowere 2
... like all important missions, require ... you to your destination. The ... this dependability. So you can ... intervention and not have to ...
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
Tests for protan and deutan defects. Patients must identify numbers or patterns formed in a matrix of small colored dots varying in color and intensity. Two editions available: 38 plate for detailed ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: